Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2016 Jan 13;23(3):228-35.
doi: 10.1128/CVI.00604-15.

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial

Andrew J Dunning  1 , Carlos A DiazGranados  2 , Timothy Voloshen  1 , Branda Hu  1 , Victoria A Landolfi  1 , H Keipp Talbot  3
Affiliations
Clinical Trial

Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial

Andrew J Dunning et al. Clin Vaccine Immunol. .

Abstract

Although a number of studies have investigated and quantified immune correlates of protection against influenza in adults and children, data on immune protection in the elderly are sparse. A recent vaccine efficacy trial comparing standard-dose with high-dose inactivated influenza vaccine in persons 65 years of age and older provided the opportunity to examine the relationship between values of three immunologic assays and protection against community-acquired A/H3N2 influenza illness. The high-dose vaccine induced significantly higher antibody titers than the standard-dose vaccine for all assays. For the hemagglutination inhibition assay, a titer of 40 was found to correspond with 50% protection when the assay virus was antigenically well matched to the circulating virus--the same titer as is generally recognized for 50% protection in younger adults. A dramatically higher titer was required for 50% protection when the assay virus was a poor match to the circulating virus. With the well-matched virus, some protection was seen at the lowest titers; with the poorly matched virus, high levels of protection were not achieved even at the highest titers. Strong associations were also seen between virus neutralization test titers and protection, but reliable estimates for 50% protection were not obtained. An association was seen between titers of an enzyme-linked lectin assay for antineuraminidase N2 antibodies and protection; in particular, the proportion of treatment effect explained by assay titer in models that included both this assay and one of the other assays was consistently higher than in models that included either assay alone. (This study has been registered at ClinicalTrials.gov under registration no. NCT01427309.).

PubMed Disclaimer

Figures

FIG 1
FIG 1
Protection curves for the A/Victoria/361/2011 HAI assay using the circulating virus against A/H3N2 illness by three laboratory-confirmed influenza (LCI) case definitions (defn.), showing titers for 50% and 80% protection, with 95% CIs.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. 2012. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 54:1427–1436. doi:10.1093/cid/cis211. - DOI - PMC - PubMed
    1. Quandelacy TM, Viboud C, Charu V, Lipsitch M, Goldstein E. 2014. Age- and sex-related risk factors for influenza-associated mortality in the United States between 1997-2007. Am J Epidemiol 179:156–167. doi:10.1093/aje/kwt235. - DOI - PMC - PubMed
    1. Haq K, McElhaney JE. 2014. Immunosenescence: influenza vaccination and the elderly. Curr Opin Immunol 29:38–42. doi:10.1016/j.coi.2014.03.008. - DOI - PubMed
    1. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, Ruiz-Palacios GM, van Essen GA, Caplanusi A, Claeys C, Durand C, Duval X, El Idrissi M, Falsey AR, Feldman G, Frey SE, Galtier F, Hwang SJ, Innis BL, Kovac M, Kremsner P, McNeil S, Nowakowski A, Richardus JH, Trofa A, Oostvogels L; for the Influence65 Study Group . 2013. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect Dis 13:485–496. doi:10.1016/S1473-3099(13)70046-X. - DOI - PubMed
    1. DiazGranados CA, Dunning AJ, Kimmel M, Kirby D, Treanor J, Collins A, Pollak R, Christoff J, Earl J, Landolfi V, Martin E, Gurunathan S, Nathan R, Greenberg DP, Tornieporth NG, Decker MD, Talbot HK. 2014. Relative efficacy of high-dose trivalent influenza vaccine compared to standard-dose vaccine in adults 65 years of age and older. N Engl J Med 371:635–645. doi:10.1056/NEJMoa1315727. - DOI - PubMed

Publication types

MeSH terms

Associated data

Grants and funding

This work was supported by Sanofi Pasteur.